OSCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OSCR is not a good buy right now for an impatient investor. The stock is in a clear downtrend (below key moving averages with worsening MACD), is trading around/under near-term support (14.76), and recent news flow has leaned negative into the Feb 10 pre-market earnings event. Options positioning is bullish-leaning (calls dominating), which can help a bounce, but without an Intellectia buy signal and with weak technical structure, the risk/reward is not attractive for an immediate entry. Best stance: HOLD/avoid new buys until price reclaims the pivot (16.16) or trend momentum improves.
Trend is bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), confirming price is trending down across long/intermediate/short timeframes. MACD histogram (-0.195) is below zero and expanding negatively, indicating downside momentum is strengthening rather than stabilizing. RSI(6) at ~29 is near oversold territory (despite being labeled neutral in the feed), which can set up a short-term bounce, but oversold conditions can persist in a strong downtrend. Key levels: Support S1=14.764 (price ~14.69 is slightly below this) and S2=13.905 (next downside level). Resistance/pivot: Pivot=16.155, then R1=17.545. The stock is also noted as ~6.8% below its 20DMA and ~14.2% below its 100DMA, reinforcing bearish structure. Pattern-based odds provided are slightly negative over week/month (-0.68% next week, -0.92% next month), not supportive of an immediate buy.
Analyst sentiment has improved recently via multiple upgrades and higher targets (Barclays to Equal Weight PT $18; UBS to Neutral PT $17), supporting a “less-bearish” narrative around subsidy-expiration fears.
Fundamentals show strong top-line growth (Q3 2025 revenue +23% YoY) and improving losses, which can support rerating if MLR/cost trends cooperate.
Options positioning is call-heavy, which can help fuel rebounds if any positive catalyst hits (earnings surprise, better medical cost commentary).
Technical downtrend is strong (bearish MA stack + worsening MACD), and price is breaking/pressuring support (~14.
with next support ~13.
News-driven pressure: Medicare Advantage payment proposal (0.09% avg increase for
and UnitedHealth’s high medical care ratio narrative are weighing on managed-care cost concerns, which can spill over to Oscar sentiment even though Oscar is ACA-exchange focused.
Event risk: Feb 10 pre-market earnings with expectations for a sizable loss (Est. EPS -0.
creates near-term uncertainty; negative guidance or cost trend commentary could push shares toward S
No supportive Intellectia signals today (no AI Stock Picker, no SwingMax), reducing confidence in timing an immediate entry.
Latest reported quarter: 2025/Q3. Revenue rose to ~$2.986B (+23.21% YoY), indicating strong growth/scale. Profitability is still negative but improving: net income -$137.45M (improvement vs prior year per feed) and EPS -$0.53 (also improved YoY). Overall: growth is strong and losses are narrowing, but the market is currently focused on medical cost trend risk and forward-year uncertainty rather than backward-looking revenue growth.
Recent trend: ratings have generally shifted more constructive since Nov, with notable upgrades and higher price targets (Piper Sandler to Overweight PT $25; Barclays to Equal Weight PT $18; UBS to Neutral PT $17; Stephens initiated Equal Weight PT $17). Bearish holdouts remain (Jefferies Underperform PT $12; Wells Fargo Underweight PT $11), largely centered on subsidy-expiration outcomes and medical loss ratio (MLR) risk. Wall Street pros: exchange enrollment resilience, pricing actions, potential margin expansion/rotation tailwinds, and a view that the market may be over-discounting subsidy risks. Cons: elevated cost/utilization concerns, MLR uncertainty, and policy/subsidy headline risk. Net: improving but still mixed; the tape/technicals are currently winning over the upgrades.
